The effect of ondansetron, a 5-HT(3) receptor antagonist, in chronic fatiguesyndrome: a randomized controlled trial.

Trial Profile

The effect of ondansetron, a 5-HT(3) receptor antagonist, in chronic fatiguesyndrome: a randomized controlled trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2010

At a glance

  • Drugs Ondansetron (Primary)
  • Indications Chronic fatigue syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Mar 2010 New trial record
    • 02 Feb 2009 Primary endpoint 'Sickness Impact Profile' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top